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TAXUS Liberté paclitaxel-eluting stent with aspirin plus prasugrel is associated with low target vessel failure, bleeding and adverse event rates among diabetic patients with "on-label" stent indications Background: Performance characteristics of the TAXUS Liberté stent in diabetic (DM) patients when combined with second-generation thienopyridine anti-platelet drugs are unknown. Methods: As part of the TAXUS Liberté paclitaxel-eluting stent post-approval study, a pre-defined subgroup of medically treated DM pts with "on-label" indications (i.e., treated as per FDA-approved labeling) for coronary stent use was studied. All were prescribed aspirin + prasugrel. The primary endpoint was target vessel failure (TVF) at 12 months; based on prior studies, the expected TVF rate was 9.0% and the performance limit for non-inferiority was 12.6%. In addition, outcomes were compared with "on-label" non-diabetic (NDM) pts. Results: Of 1592 enrolled pts meeting "on-label" criteria, 505 (31.7%) were diabetic: 68% male, mean age 60.6 years, 19.8% smoked, 39.4% presented with stable angina, 31.9% unstable angina, 0.6% NSTEMI (none with STEMI). More than 99% had a de novo lesion treated. Lesion types B2 and C were 14.1 and 8%. The primary endpoint of TVF occurred in 25 (5.1%) DM pts; the upper 1-sided 95% confidence interval was 6.8%, well below the performance limit of 12.6% (p<0.0001). Four deaths (0.8%, none attributable to the TAXUS Liberté stent), 4 NSTEMI, and 3 strokes were observed. Major bleeding occurred in 8 (1.6%) and stent thrombosis occurred in 1 pt. Compared with NDM, DM pts were more likely to be overweight, have metabolic syndrome, hyperlipidemia and hypertension but less likely to smoke. Lesion complexities were similar but DM vessels were smaller and NDM lesions longer and more likely to contain thrombus. TVF and clinical outcomes, including GUSTO moderate or severe bleeding, were similar for DM and NDM patients.
Conclusions: We observed low rates of TVF at 1 year during post-approval clinical use of TAXUS Liberté PES in DM pts with "on-label" indications and taking aspirin + prasugrel. TVF and clinical outcomes were similar to those observed among NDM pts. Bleeding rates were low for "on-label" DM and NDM patients. These data suggest potential benefit with use of second-generation PES combined with ASA and prasugrel in selected DM pts including those without acute coronary syndromes. Background: High platelet reactivity (HPR) on ADP receptor inhibitor treatment (ADPri) is associated with increased risk of adverse events, yet there are no guidelines on its management. Methods: We studied 1,505 acute MI patients treated with PCI at 62 US hospitals in the TRANSLATE-ACS study from 4/2010 to 10/2012. All patients received either a 1st generation (clopidogrel or ticlopidine) or 2nd generation (prasugrel or ticagrelor) ADPri and underwent platelet reactivity testing using the VerifyNow assay at a median of 2 days after PCI. We used logistic regression modeling to determine factors associated with HPR (platelet reactivity unit [PRU] >235), and examined rates of treatment change in response to platelet function testing. Results: Overall, HPR was observed in 361 (24%) of this acute MI population, more frequently among patients treated with 1st generation (29%) than those treated with 2nd generation ADPri (7%). HPR was independently associated with patient age (OR 1.18, 95%CI 1.04-1.34, per 10 year increase, p¼0.01), female sex (OR 1.60, 95%CI 1.23-2.08, p<0.001), BMI (OR 1.04, 95%CI 1.02-1.06, per 1kg/m2 increase, p<0.001) and treatment with 1st generation ADPri (OR 3.12, p<0.001) . After platelet function testing, ADPri was switched from 1st to 2nd generation in 37% of patients with HPR compared with 10% of patients with therapeutic platelet reactivity (TPR), while 8% of patients with HPR and 6% of patients with TPR were switched from a 2nd to 1st generation ADPri. Conclusions: While the value of modifying treatment based on platelet function testing remains unclear, we found that ADPri therapy was frequently altered when HPR was detected. Further evaluation of clinical outcomes associated with modification of ADPri therapy among PCI treated MI patients with HPR is warranted. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
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